Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients : An Observational Cohort Study Based on SEER-Medicare
المؤلفون المشاركون
Danese, Mark D.
Griffiths, Robert I.
Gleeson, Michelle L.
Mikhael, Joseph
المصدر
Journal of Cancer Epidemiology
العدد
المجلد 2012، العدد 2012 (31 ديسمبر/كانون الأول 2012)، ص ص. 1-13، 13ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2012-08-27
دولة النشر
مصر
عدد الصفحات
13
التخصصات الرئيسية
الملخص EN
Rituximab improves survival in follicular lymphoma (FL), but is considerably more expensive than conventional chemotherapy.
We estimated the total direct medical costs, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for FL, based on a single source of data representing routine practice in the elderly.
Using surveillance, epidemiology, and end results (SEER) registry data plus Medicare claims, we identified 1,117 FL patients who received first-line CHOP (cyclophosphamide (C), doxorubicin, vincristine (V), and prednisone (P)) or CVP +/− rituximab.
Multivariate regression was used to estimate adjusted cumulative cost and survival differences between the two groups over four years after beginning treatment.
The median age was 73 years (minimum 66 years), 56% had stage III-IV disease, and 67% received rituximab.
Adding rituximab to first-line chemotherapy was associated with higher adjusted incremental total cost ($18,695; 95% Confidence Interval (CI) $9,302–$28,643) and longer adjusted cumulative survival (0.18 years; 95% CI 0.10–0.27) over four years of followup.
The expected cost-effectiveness was $102,142 (95% CI $34,531–296,337) per life-year gained.
In routine clinical practice, adding rituximab to first-line chemotherapy for elderly patients with FL results in higher direct medical costs to Medicare and longer cumulative survival after four years.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Griffiths, Robert I.& Gleeson, Michelle L.& Mikhael, Joseph& Danese, Mark D.. 2012. Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients : An Observational Cohort Study Based on SEER-Medicare. Journal of Cancer Epidemiology،Vol. 2012, no. 2012, pp.1-13.
https://search.emarefa.net/detail/BIM-513038
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Griffiths, Robert I.…[et al.]. Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients : An Observational Cohort Study Based on SEER-Medicare. Journal of Cancer Epidemiology No. 2012 (2012), pp.1-13.
https://search.emarefa.net/detail/BIM-513038
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Griffiths, Robert I.& Gleeson, Michelle L.& Mikhael, Joseph& Danese, Mark D.. Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients : An Observational Cohort Study Based on SEER-Medicare. Journal of Cancer Epidemiology. 2012. Vol. 2012, no. 2012, pp.1-13.
https://search.emarefa.net/detail/BIM-513038
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-513038
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر